These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34314387)

  • 1. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome.
    Gao DK; Salomonis N; Henderlight M; Woods C; Thakkar K; Grom AA; Thornton S; Jordan MB; Wikenheiser-Brokamp KA; Schulert GS
    JCI Insight; 2021 Sep; 6(17):. PubMed ID: 34314387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
    Schulert GS; Pickering AV; Do T; Dhakal S; Fall N; Schnell D; Medvedovic M; Salomonis N; Thornton S; Grom AA
    Ann Rheum Dis; 2021 May; 80(5):617-625. PubMed ID: 33277241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
    Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
    Chen G; Deutsch GH; Schulert GS; Zheng H; Jang S; Trapnell B; Lee PY; Macaubas C; Ho K; Schneider C; Saper VE; de Jesus AA; Krasnow MA; Grom A; Goldbach-Mansky R; Khatri P; Mellins ED; Canna SW
    Arthritis Rheumatol; 2022 Jul; 74(7):1271-1283. PubMed ID: 35189047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
    Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
    PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
    Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
    Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).
    Verweyen EL; Schulert GS
    Rheumatology (Oxford); 2022 Mar; 61(3):926-935. PubMed ID: 34459891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Lu M; Teng L; Xu Y; Xu X
    Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome.
    Inoue N; Schulert GS
    Arthritis Res Ther; 2023 Mar; 25(1):48. PubMed ID: 36964620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.
    Prencipe G; Caiello I; Pascarella A; Grom AA; Bracaglia C; Chatel L; Ferlin WG; Marasco E; Strippoli R; de Min C; De Benedetti F
    J Allergy Clin Immunol; 2018 Apr; 141(4):1439-1449. PubMed ID: 28807602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings from the 2
    Canna SW; Schulert GS; de Jesus A; Pickering A; Brunner H; Gadina M; Levine S; Goldbach-Mansky R; Boutelle J; Sinha R; DeBenedetti F; Grom A;
    Pediatr Rheumatol Online J; 2020 Jul; 18(Suppl 1):53. PubMed ID: 32664935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage activation syndrome: advances towards understanding pathogenesis.
    Grom AA; Mellins ED
    Curr Opin Rheumatol; 2010 Sep; 22(5):561-6. PubMed ID: 20517154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.
    Vandenhaute J; Wouters CH; Matthys P
    Front Immunol; 2019; 10():3089. PubMed ID: 32010140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
    Yasin S; Schulert GS
    Curr Opin Rheumatol; 2018 Sep; 30(5):514-520. PubMed ID: 29870499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Chellapandian D; Milojevic D
    Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice.
    Girard-Guyonvarc'h C; Palomo J; Martin P; Rodriguez E; Troccaz S; Palmer G; Gabay C
    Blood; 2018 Mar; 131(13):1430-1441. PubMed ID: 29295842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung Functioning and Inflammation in a Mouse Model of Systemic Juvenile Idiopathic Arthritis.
    Malengier-Devlies B; Decaesteker T; Dekoster K; Vanstapel A; Ahmadzadeh K; Poosti F; Mitera T; Seldeslachts L; Verbeken E; Wouters C; Vande Velde G; Vanoirbeek J; Matthys P
    Front Immunol; 2021; 12():642778. PubMed ID: 33777039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
    Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
    J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.